MAP Verified Summary — reported by STAT News
A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.
This story was scored across MAP’s five-signal verification framework — Context, Presentation, References, Visibility, and Comparison — as part of Media Alert Press’s independent media credibility index. Read the full original story at STAT News →
Discover more from Media Alert Press
Subscribe to get the latest posts sent to your email.